Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA refuses to accept Theravance's re-submission of Vibativ for hospital-acquired pneumonia

This article was originally published in Scrip

Executive Summary

The US FDA has dealt a major blow to Theravance's quest to gain a supplemental hospital-acquired pneumonia (HAP) indication for its injectable broad-spectrum antibiotic Vibativ (telavancin) by refusing to accept two Phase III studies that are supporting the sNDA as separate entities, since their primary endpoint data were pooled together.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts